Safety information for industry
The Australian community expects therapeutic goods in the marketplace to be safe, of high quality and of a standard at least equal to that of comparable countries.
The pages linked below contain information for sponsors and manufacturers.
- Product recalls
A product recall is the removal of a therapeutic good from supply on the Australian market for reasons relating to their quality, efficacy or safety
Links to safety alerts and advisory statements about medicines and medical devices in Australia.
- Uniform recall procedure for therapeutic goods (URPTG)
The Uniform Recall Procedure for Therapeutic Goods defines the action to be taken by health authorities and sponsors when therapeutic goods for use in humans, for reasons relating to their quality, safety or efficacy, are to be removed from supply or use, or subject to corrective action
- Product contamination & extortion - a protocol for the therapeutic goods industry
Developed by the Industry Government Crisis Management Committee as a joint industry-government initiative, with the aim of assisting managers in responding to a product contamination and/or extortion event directed at the therapeutic goods industry
- Human blood & tissues recall report form
This form is used to report recalls of human blood and tissue products
- Report a medical device adverse event (sponsor/manufacturer)
This form is to be used by medical device manufacturers or authorised representatives for mandatory reporting of adverse events associated with a medical device
- Medicines safety monitoring
How the safety of medicines is monitored, including guidelines for sponsors and manufacturers
- Medical devices safety monitoring
How the safety of medical devices is monitored, including guidelines for sponsors and manufacturers
- Transmissible Spongiform Encephalopathies (TSE): TGA approach to minimising the risk of exposure
TSEs, caused by agents known as prions, include scrapie in sheep and goats, chronic wasting disease in deer, bovine spongiform encephalopathy (BSE) in cattle, and Kuru and Creutzfeldt-Jacob Disease (CJD) in humans
- Supplementary information on Transmissible Spongiform Encephalopathies (TSEs) regulation
Supplementary information on changes the TGA has made in updating its approach to minimising the transmission of Transmissible Spongiform Encephalopathies (TSEs)
Web page last updated: Wednesday, 9 April 2014